ATG5 and metabolic dysfunction-associated steatotic liver disease: Studies have shown that the inhibition of autophagy-related genes such as autophagy protein 5 (ATG5) increases hepatic lipid content and accelerates liver injury, indicating that enhancing autophagic activity may be a therapeutic strategy to mitigate NAFLD progression [47].